Start here if you're new
what it is
Central sells branded pet supplies and lawn-and-garden products through pet stores, big-box retailers, groceries, and home improvement chains.
how it gets paid
Last year Central Gdn. & Pet made $3.1B in revenue. Pet food, treats & habitat was the main engine at $0.99B, or 32% of sales.
why growth slowed
Revenue fell 2.2% last year. The 6% sales decline matters most because this is a scale business.
what just happened
Latest quarter revenue fell 6% to $617M, and profit got hit even harder.
At a glance
B+ balance sheet — decent shape, but not bulletproof
70/100 earnings predictability — reasonably predictable
15.3x trailing p/e — the market's not buying it — or you found a deal
6.5% return on capital — nothing to write home about
xvary composite: 57/100 — below average
What they do
Central sells branded pet supplies and lawn-and-garden products through pet stores, big-box retailers, groceries, and home improvement chains.
This is not a magic-brand story. It is a shelf-space story. Pet products made up 58% of fiscal 2025 sales and garden made up 42%, which means retailers already give Central room across two aisles you probably shop every season. Scale matters here. $3.1 billion in annual revenue and 5,700 employees buy you distribution reach, and distribution reach → getting your products in more stores → more chances your cart already has their stuff in it.
How they make money
$3.1B
annual revenue · their business grew -2.2% last year
Dog & cat supplies
$0.81B
Pet food, treats & habitat
$0.99B
Grass seed & garden controls
$0.74B
Wild bird & outdoor living
$0.56B
The products that matter
sells pet and garden goods
Pet and Garden Portfolio
$3.1B revenue · entire business
it's the whole $3.1B business, and that top line slipped 2.2% last year. when the entire portfolio slows, there is nowhere else to hide.
100% of revenue
Key numbers
58%
pet mix
More than half of sales come from pet products, which are usually less seasonal than garden and help steady the business.
$1.2B
long-term debt
Debt is real leverage → borrowed money → less flexibility if weak sales last longer than expected.
11.0%
operating margin
Operating margin → profit before interest and taxes → shows the core business is decent, but not built like a luxury tollbooth.
15.3x
trailing p/e
P/E → stock price divided by profit → says you are paying a middle-of-the-road price for a middle-of-the-road operator.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 65 / 100
- long-term debt $1.2B (33% of capital)
- net profit margin 5.7% — keeps 6 cents of every dollar in revenue
- return on equity 10% — $0.10 profit for every $1 investors have put in
B+ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in CENT 3 years ago → it's now worth $12,230.
The index would have given you $14,540.
source: institutional data · total return
What just happened
missed estimates
Latest quarter revenue fell 6% to $617M, and profit got hit even harder.
EDGAR shows quarterly revenue of $617M and EPS of $0.11, down 48% vs. prior year. Gross margin held at 30.9%, but softer demand still dragged results.
$617M
revenue
$0.11
eps
30.9%
gross margin
the number that mattered
The 6% sales decline matters most because this is a scale business, and smaller volume can squeeze a 5.7% net margin fast.
-
central pet & garden began fiscal 2026 on a soft note. (year ends september 30th.) december-period sales fell 6% vs. prior year, owing in large part to the timing of retailer spring inventory shipments.last year, seasonal load-ins for the garden segment, and to some extent the pet division, were heavily concentrated in the first quarter. even though the company has made a lot of progress on its ‘‘cost and simplicity’’ program and restructuring efforts (discussed below), the bottom line came in flat for the term.
-
the company is poised to do well this year, despite challenging operating conditions.
-
wavering consumer sentiment may dampen demand for many of its offerings in the coming months.
-
consequently, we imagine sales will come in flat for fiscal 2026.on the other hand, portfolio management, pricing actions, and supply-chain improvements ought to limit the negative impact of tariff exposure.
-
and other growth initiatives should begin to take hold, aiding the bottom line.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is another weak spring selling season in lawn and garden.
med
spring demand stays soft
A lot of this story depends on consumers showing up for pet and garden purchases when the season turns. If that demand slips again, the revenue line can keep moving the wrong way.
impact: with the full $3.1B business exposed to end-demand, another negative sales year would keep the valuation discount intact.
med
input and freight costs rise faster than pricing
This is a 30.9% gross margin quarter and a 5.6% net margin business. That is not a lot of cushion.
impact: when margins are already thin, even modest cost inflation can turn a small EPS miss into a much larger percentage drop.
med
retail shelf space and promotion pressure
Central sells through retailers, which means shelf placement, pricing, and promotions are not controlled entirely in-house. Brand recognition helps, but it does not guarantee pricing power.
impact: if retailers push for more discounts, a 5.6% net margin can compress fast.
with $3.1B in revenue and just a 5.6% net margin, this business does not need a crisis to disappoint you. it just needs one more soft season.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
spring selling season
this is the clearest near-term tell. if seasonal demand disappoints again, the revenue decline story stays alive.
metric
gross margin
30.9% was the last reported quarter. in a thin-margin business, this number does a lot of the talking.
trend
top-line direction
annual revenue was down 2.2% and the quarter was down 6%. you want to see that slide stop before you pay up for a rerating.
risk
debt versus earnings power
$1.2B in long-term debt is manageable with steady demand. it feels heavier when margins and sales both soften.
Analyst rankings
short-term outlook
average
momentum score 3. in human-speak, analysts do not see a clear catalyst pushing this stock ahead of the pack in the next year.
risk profile
average
stability score 3. this sits in the middle — not a bunker stock, not a chaos stock.
chart momentum
bottom 5%
technical score 5 is the weakest rating. the chart is saying "show me" before it gives management any benefit of the doubt.
earnings predictability
70 / 100
reasonably predictable, but not clean enough that you can ignore quarterly variance.
source: institutional data
Institutional activity
55 buyers vs. 51 sellers in 4q2025. total institutional holdings: 9.4M shares.
source: institutional data
Price targets
3-5 year target range
$30
$55
$39
current price
$43
target midpoint · +11% from current · 3-5yr high: $65 (+65% · 14% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive